Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug;50(8):2548-52.
doi: 10.1128/JCM.00775-12. Epub 2012 May 16.

Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections

Natasha E Holmes  1 , Paul D R Johnson, Benjamin P Howden
Affiliations
Review

Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections

Natasha E Holmes et al. J Clin Microbiol. 2012 Aug.

Abstract

Vancomycin has been used successfully for over 50 years for the treatment of Staphylococcus aureus infections, particularly those involving methicillin-resistant S. aureus. It has proven remarkably reliable, but its efficacy is now being questioned with the emergence of strains of S. aureus that display heteroresistance, intermediate resistance, and, occasionally, complete vancomycin resistance. More recently, an association has been established between poor outcome and infections with strains of S. aureus with an elevated vancomycin MIC within the susceptible range. This minireview summarizes the definitions, mechanisms, clinical impact, and laboratory identification of reduced vancomycin susceptibility in S. aureus and discusses practical issues for the diagnostic laboratory in testing and interpreting vancomycin susceptibility for S. aureus infections.

PubMed Disclaimer

References

    1. British Society for Antimicrobial Chemotherapy (BSAC) 2011. BSAC methods for antimicrobial susceptibility testing, version 10.2 British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom: http://www.bsac.org.uk/Susceptibility+Testing/Breakpoints
    1. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448–451 - PubMed
    1. Clinical and Laboratory Standards Institute (CLSI) 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—seventh edition. CLSI document M07-A7. CLSI, Wayne, Philadelphia, PA
    1. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276–2285 - PMC - PubMed
    1. Elsaghier AA, Aucken HM, Hamilton-Miller JM, Shaw S, Kibbler CC. 2002. Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. J. Antimicrob. Chemother. 49:423–424 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources